Table 2 Second round questionnaire to 40 experts on inotrope use
Question | Answer |
|---|---|
In a terminological sense (when discussing with fellow colleagues and/or researchers), do you refer to norepinephrine as a vasopressor? | |
 Exclusively a vasopressor | 65% |
 It is context dependent and not a fixed term in discussions with fellow colleagues and/or researchers | 35% |
In your physiological understanding and your treatment approach, do you consider norepinephrine: | |
 Exclusively a vasopressor (i.e., you only use it to modify blood pressure) | 42% |
 A vasopressor and an inotrope (i.e., in your treatment strategy, you consider it a drug to efficiently modify both blood pressure and cardiac output) | 57% |
What is your first-line inotrope? | |
 Dobutamine | 82% |
 Epinephrine | 5% |
 Levosimendan | 2% |
 Milrinone | 2% |
 Norepinephrine | 8% |
Do you recommend a PDE-inhibitor in right ventricular failure? | |
 Yes | 65% |
 No | 35% |